Several other analysts have also issued reports on PETQ. Zacks Investment Research upgraded shares of PetIQ from a hold rating to a buy rating and set a $36.00 price target on the stock in a research report on Friday, August 9th. Guggenheim assumed coverage on shares of PetIQ in a research report on Thursday, May 23rd. They set a buy rating and a $35.00 price objective for the company. Finally, ValuEngine cut PetIQ from a buy rating to a hold rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $41.33.
PETQ opened at $27.70 on Friday. The stock has a market capitalization of $781.75 million, a price-to-earnings ratio of 22.16, a P/E/G ratio of 1.07 and a beta of 2.09. The company has a quick ratio of 1.66, a current ratio of 2.97 and a debt-to-equity ratio of 0.33. PetIQ has a twelve month low of $21.29 and a twelve month high of $43.93. The company has a 50-day simple moving average of $32.18 and a 200 day simple moving average of $30.66.
PetIQ (NASDAQ:PETQ) last released its earnings results on Wednesday, August 7th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.35 by $0.35. The firm had revenue of $220.60 million for the quarter, compared to analyst estimates of $193.89 million. PetIQ had a net margin of 0.68% and a return on equity of 10.17%. The business’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period last year, the firm earned $0.66 EPS. Sell-side analysts anticipate that PetIQ will post 1.07 EPS for the current fiscal year.
In other PetIQ news, insider Will Santana sold 20,000 shares of PetIQ stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $35.85, for a total value of $717,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 80,291 shares of company stock worth $2,647,491. Company insiders own 23.79% of the company’s stock.
A number of institutional investors have recently modified their holdings of PETQ. Manchester Capital Management LLC bought a new position in shares of PetIQ in the 1st quarter valued at $30,000. Bank of Montreal Can bought a new position in shares of PetIQ during the second quarter valued at $53,000. US Bancorp DE raised its stake in shares of PetIQ by 461.5% during the second quarter. US Bancorp DE now owns 2,246 shares of the company’s stock valued at $74,000 after acquiring an additional 1,846 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of PetIQ during the second quarter valued at $80,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of PetIQ by 327,900.0% during the first quarter. BNP Paribas Arbitrage SA now owns 3,280 shares of the company’s stock worth $103,000 after purchasing an additional 3,279 shares during the period. Hedge funds and other institutional investors own 91.80% of the company’s stock.
PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.
Featured Story: What is a stock split?
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.